POET Technologies Booked $569,925 of Revenue and a $50 Million Purchase Order in the Same Quarter

by Karl Lindström · August 16, 2026

Semiconductors & Hardware Reporter, Frontier Tech Wire

POET Technologies reported second-quarter results before the opening bell on Thursday, August 13, 2026, and the release sets two numbers awkwardly beside one another. Revenue for the quarter was $569,925. An initial purchase order recapped in the same document — first announced in a separate release on May 14, 2026, and so falling inside the same quarter — is valued at $50 million. The distance between those two figures is the whole of the investment question at POET right now, and the disclosure resolves less of it than the headline suggests.

Start with what is firmly established. The company said quarterly revenue of $569,925 was up 112% from the $268,469 it recorded in the second quarter of 2025, and up 13% from the $503,389 it reported in the first quarter of 2026. POET described it as the sixth consecutive quarter of sequential revenue growth. Adding the two reported quarters gives first-half 2026 revenue of $1,073,314; the release itself presents quarterly figures only and does not publish six-month totals. These are the company's own figures, disclosed in its earnings release issued through GlobeNewswire at 07:01 Eastern on August 13. POET reports under IFRS rather than United States GAAP.

Percentage growth off a base this small is a weak signal on its own, and it is worth being plain about the arithmetic. The $50 million initial purchase order is roughly 87 times the revenue POET recognised in the entire quarter in which it was announced, and roughly 47 times its first-half revenue. Nothing about that ratio is inherently damning for a company moving from development into production. It does mean that essentially all of the order's significance depends on execution details, and those details are only partly disclosed.

On the agreement itself, the second-quarter release says POET "entered into a supply agreement that establishes a strategic joint development and commercial technology partnership to advance a new class of wafer-level photonic integration for frontier AI infrastructure." It continues that the supply agreement "establishes a commercial framework to support the joint development program, and, as part of that framework, Lumilens has placed an initial purchase order with the Company for the manufacturing of POET Optical Interposer-based engines valued at $50 million."

The release then repeats a forward-looking figure that has travelled further than the order itself: the purchase order "represents the first phase of a broader supplier relationship that could scale to $500+ million in cumulative purchases from the Company over five years." That sentence appears in the narrative of both the May 14 announcement and the August 13 earnings release; it is not attributed to any named executive, and it is not inside a quotation. The operative word is "could." Neither release attaches milestones, minimum volumes, a committed schedule or a contractual mechanism by which the $50 million becomes $500 million. It is a description of an opportunity, not a disclosed obligation, and it should be read as one.

Some of what a reader would want to know is disclosed, and some is not, and the two should not be run together. The May 14 announcement does identify the counterparty: it describes Lumilens as a company "building the connectivity platform for AI infrastructure" that "designs, develops, and manufactures near-package optics, co-packaged optics, and pluggable optical transceivers for hyperscale AI data centers," and says it is "backed by Mayfield, Spark Capital, and other leading venture capital investors." That release also carries a quote from Lumilens chief executive Ankur Singla and gives a programme timeline: engineering samples "expected in late 2026, with production ramp aligned to hyperscaler customer deployments in 2027." The August 13 earnings release, by contrast, carries none of that description.

What neither release states is whether the purchase order is binding, cancellable, or contingent on qualification milestones; what the unit pricing or volumes are; what the delivery schedule for the $50 million of engines specifically is, as distinct from the programme-level sample-and-ramp timeline; and over what period any portion of the order would be recognised as revenue. Those are the gaps, and they are the ones that matter for converting the number into results.

The closest the earnings release comes to a company-wide timeline is a separate operational statement: "The Company expects to begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026 and will make additional announcements and updates in September, subject to the prevailing confidentiality agreements and the risks described under 'Cautionary Note Regarding Forward-Looking Information' below." Qualification shipments are a distinct thing from fulfilment of a commercial order. Units shipped so a customer can qualify a part are a step toward volume production, not evidence that volume production has begun, and the release does not connect that sentence to the Lumilens order or to any revenue figure.

Chairman and Chief Executive Suresh Venkatesan framed the quarter this way: "The second quarter showed POET's transition from development to revenue taking hold: our sixth consecutive quarter of sequential revenue growth, a narrowing net loss, and our optical engine production ramp remaining on schedule for the second half of 2026."

The loss line did narrow. POET reported a second-quarter net loss of $11.3 million, or $(0.07) per share, against a net loss of $12.3 million, or $(0.08) per share, in the first quarter of 2026, and $17.3 million, or $(0.21) per share, in the second quarter of 2025. Summing the two reported quarters gives a first-half loss of about $23.6 million; the release does not present a six-month total. It does present a separate "Non-IFRS Financial Summary" that splits NRE from product revenue and identifies non-cash items, so the reported loss is not the only measure the company puts forward.

Two of the items that narrowed the loss are worth naming, because neither reflects the operating business. The release discloses a derivative liability adjustment of $5,531,784 — a non-cash remeasurement of warrant-related liabilities — and other income including interest of $4,299,496, which is what a cash balance of this size now generates. A loss that improves partly on a non-cash mark and partly on interest income is a different thing from a loss that improves on gross margin, and the release's own line items make that distinction available.

One qualifier belongs on the per-share improvement. POET issued 19,047,620 new common shares in a May offering described below, which enlarges the denominator. A per-share loss that falls from $(0.21) to $(0.07) year over year therefore reflects both a smaller absolute loss and a substantially larger share count, and the two effects should not be read as one.

The release itemises selected expense lines for the quarter rather than a full statement of operations: research and development of $5,784,056, stock-based compensation of $3,816,906, wages and benefits of $2,778,119, depreciation and amortisation of $1,026,953, professional fees of $725,691, general expenses and rent of $456,171, finance advisory fees of $6,172,500, and interest expense of $67,894. The finance advisory line is a large one-off tied to the May financing rather than a run-rate cost. Against those charges the release discloses offsetting items: the $5,531,784 derivative liability adjustment, $4,299,496 of other income including interest, and $910,975 of unrealized foreign exchange income, together with the $569,925 of revenue. Netting the disclosed lines leaves roughly $9.5 million against a reported net loss of $11.3 million, so the summary does not fully itemise every line in the statement — but the substance of the gap is disclosed in the release, not missing from it. The complete statement of operations sits in the interim financial statements rather than the earnings summary.

The balance sheet is the least ambiguous part of the disclosure. "The Company ended the quarter with $796.3 million in cash and short-term investments following completion of its $400 million financing in May," the release says. That is the label the company uses, and it is worth preserving precisely: it is a combined cash-and-short-term-investments figure, not a cash-only balance, and the two are not interchangeable. It is also consistent with the prior quarter's filing, which put cash, cash equivalents and short-term investments at $429,136,442 as of March 31, 2026 — before the $400 million arrived.

The cash arrived in May. POET closed a registered direct offering of 19,047,620 units at $21.00 per unit for gross proceeds of $400,000,020, in a non-brokered transaction with a single institutional investor whose identity the company did not disclose. Each unit comprised one common share and one common share purchase warrant, with each warrant exercisable for three years from closing — to May 18, 2029 — at $26.25. The company said the price was a premium to market, citing a prior-day Nasdaq close of $20.57 on May 17, 2026. Those are transaction terms from the closing release, not current market prices: United States equity markets have been closed since Friday, August 14, and this article carries no trading prices.

The warrant structure carries an arithmetic consequence worth stating plainly, since both inputs are disclosed: 19,047,620 warrants exercisable at $26.25 would represent approximately $500 million of additional gross proceeds if every one of them were exercised, along with a corresponding increase in shares outstanding. Whether any are exercised depends on conditions between now and May 2029 that no source addresses and that we are not going to forecast.

Venkatesan addressed the financing directly: "The $400 million strategic investment we completed in the quarter — priced at a premium to market — fundamentally strengthens POET's financial position, removes the uncertainty associated with our staying power and enables management to focus entirely on executing our commercial and operational objectives. This amount of capital positions POET to accelerate the expansion of our manufacturing capacity in support of anticipated customer demand, including the commercialization and production ramp associated with our collaboration with Lumilens."

The company also announced the appointment of Dr. Sandeep Kumar as Chief Operating Officer. Venkatesan's third quoted remark in the release addresses it: "The appointment of Dr. Sandeep Kumar as Chief Operating Officer adds the operational and manufacturing leadership required as we scale our global operations. Together, our strengthened leadership team, significantly enhanced capital resources and expanding commercial opportunities establish the foundation for the next phase of POET's growth and positions the Company to deliver long-term value for customers and shareholders." The release does not disclose compensation terms or a start date for the appointment.

A listing note, because this beat has burned people on exactly this point. POET Technologies trades on the Nasdaq Capital Market under the symbol POET, and only there; the August 13 release and the May financing release both carry the Nasdaq line and neither mentions any Canadian listing. The company voluntarily delisted from the TSX Venture Exchange, where it had traded as PTK, "effective as of the close of trading on or about Wednesday, August 27, 2025," telling shareholders at the time that "the listing of POET's Shares on Nasdaq will be unaffected." Quote pages and aggregator round-ups still surface the retired TSXV line. POET is also a Canadian issuer that reports to the SEC as a foreign private issuer — its filings identify Form 20-F as its annual reporting form — which is why its quarterly disclosure arrives on Form 6-K rather than a Form 10-Q.

What is genuinely testable from here is narrow and dated. POET has told investors it expects to begin shipping substantial numbers of production units for qualification across the remaining quarters of 2026, with further updates promised in September. Whether those qualification shipments convert into recognised revenue, and on what schedule any portion of the $50 million order lands, are questions the third-quarter report is the first document positioned to answer. Until then the $50 million and the $500 million are figures describing an agreement, and the $569,925 is the figure describing the business.